IRCT20080902001181N4招募中3 期
Comparison of the effect of Agnugol, Cimifugol , Soyagol , vitagnus and EsCitalopram in reducing menopausal symptoms in postmenopausal women
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 45 years 至 65 years（—）
- 性别
- Female
入选标准
- •Obtaining a score of 5 and above from the MRS questionnaire
- •12 months or more have passed since menopause
- •Age between 45 and 65 years
排除标准
- •Presence or history of breast and uterine cancer, abnormal vaginal bleeding, liver, kidney, thyroid, depression and known anxiety disorders.
- •Use of progestins, contraceptive pills, GNRH agonists and antagonists
- •Taking drugs that interact with the studied drugs, such as warfarin, tamoxifen, antipsychotics, and dopamine antagonists.
研究者
相似试验
已完成
3 期
Comparative evalution of Cimifugol and Salvigol effect on hot flash ,night sweating in menopausal women attending to Hamadan health care centers in 2016Symptoms of Menopause.Menopausal and female climacteric statesIRCT2016070723640N5Vice chancellor for research, Hamadan University of Medical Sciences80
已完成
2 期
The effect of agnogl on oligomenorrhea in polycystic ovary syndromeOligomenorrhea.-IRCT2015072623350N1Vice Chancellor for research, Hamadan University of Medical Sciences120
已完成
4 期
Comparative investigation of the effect of Fenugreek seed - flax seed and soy on the severity of depression at menopauseDepression.Depressive episodeIRCT201110262545N2Vice chancellor for research Arak University of Medical Sciences.120
进行中（未招募）
1 期
Efficacy and safety of semaglutide versus canagliflozin as add-on to metformin in subjects with type 2 diabetesMedDRA version: 20.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 2EUCTR2016-000989-35-GBovo Nordisk A/S788
进行中（未招募）
3 期
The aim of the trial is to compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0 mg) versus once-daily dosing of oral canagliflozin (300 mg) on glycaemic control in subjects with type 2 diabetes (T2D) on a background treatment of metformiCTRI/2017/07/009081ovo Nordisk India Private Ltd50